# Immune endocrine damage is usually permanent, and almost nobody is told

Source: https://onco.cc/technologies/rejuv-recovery-endocrine-permanence/  
OnCo record `rejuv-recovery-endocrine-permanence` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most immune side effects of checkpoint inhibitors settle. The hormone glands are the exception: a pituitary, thyroid, adrenal or insulin-making gland destroyed by the immune system does not grow back, and the replacement treatment that follows is usually for life. In the follow-up cohorts 83 per cent of hormone problems were still present three months after the drug stopped.

## Summary

The consent conversation for a checkpoint inhibitor is, reasonably, about the toxicities that can kill: colitis, hepatitis, pneumonitis, myocarditis. Those are the ones that are treated with steroids and that mostly resolve. The hormone glands behave in the opposite way, and the long-term cohorts have measured it.

In 387 patients given adjuvant anti-PD-1 after melanoma surgery and followed after the drug stopped, hormone problems persisted in 73 of 88 cases (83.0 per cent), while colitis became chronic in only 6 of 44 and four of those six later resolved. An extended follow-up of 318 patients at six centres in the United States and Australia found immune side effects still present in 93 patients at a median of 1,057 days, and of the 24 still on systemic steroids, 16 were on replacement for hypophysitis or adrenal insufficiency.

Gland by gland the picture is consistent. In a tertiary clinic cohort of 22 people with checkpoint hypophysitis, none recovered the pituitary control of the adrenal gland during follow-up, while the thyroid axis recovered in 33 per cent and the gonadal axis in 67 per cent. Of 103 patients with checkpoint-associated thyroiditis, 2 regained their own thyroid function and 64 reached normal levels on levothyroxine. In the CANDIED cohort of checkpoint-induced insulin-dependent diabetes across five Canadian centres, every one of the 34 patients remained insulin-dependent.

Why this matters practically: the symptoms are exhaustion, nausea, dizziness and low mood, which is also what cancer treatment feels like, so the diagnosis is easy to miss and the test is a blood test. Untreated adrenal insufficiency can kill in an intercurrent illness or an operation. Replacement is cheap and effective, and nothing about any of this is an argument against a treatment that cures people who would once have died. It is an argument for saying so at the start, and for a hormone profile at the first hint rather than the third.

## Fields

- Kind: Technology
- Status: established
- Last checked: 2026-10-02
- Tags: rejuvenation; survivorship; evidence:strong; late-effects; irae
- Principle: T cells released from checkpoint restraint infiltrate endocrine tissue and destroy hormone-secreting cells. The destruction is clonal and irreversible, unlike the lymphocytic inflammation of the gut or liver, which resolves when the infiltrate is suppressed. Steroids treat the inflammation but do not regenerate the gland, which is why endocrine events are the one group where guidelines allow the checkpoint inhibitor to continue: stopping it does not restore the gland, and hormone replacement controls the consequence.
- Strengths: The replacement treatments are cheap, well understood and effective for life; The diagnosis is a blood test available in any hospital; Endocrine events usually do not require the cancer treatment to be stopped
- Limitations: The gland does not recover, so this is management rather than cure; The symptoms overlap with the cancer and with treatment fatigue, so diagnosis is often late; Most consent conversations describe immune side effects as reversible without naming the exception

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Hypophysitis
- Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma (JAMA Oncol 2021): https://doi.org/10.1001/jamaoncol.2021.0051
- Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy (JAMA Netw Open 2023): https://doi.org/10.1001/jamanetworkopen.2023.27145
- Checkpoint inhibitor hypophysitis in a tertiary centre (Clin Endocrinol 2026): https://doi.org/10.1111/cen.70137
- Levothyroxine dosing in checkpoint-associated hypothyroidism (Thyroid 2022): https://doi.org/10.1089/thy.2021.0685
- Checkpoint inhibitor-induced insulin-dependent diabetes, CANDIED (Cancers 2021): https://doi.org/10.3390/cancers14010089

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [What comes back after treatment, treatment by treatment](https://onco.cc/technologies/rejuv-recovery-matrix/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- terms: [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/), [Late effects and survivorship toxicity](https://onco.cc/terms/late-effects/)
- bottlenecks: [Survivorship and late effects are neglected](https://onco.cc/bottlenecks/b-survivorship/), [Toxicity and quality of life are undervalued](https://onco.cc/bottlenecks/b-toxicity-qol/)

---
JSON: https://onco.cc/api/v1/entities/rejuv-recovery-endocrine-permanence.json